Share This Page

Support & Insight for the Autumn of Life

2012 Drug Trials Edge Towards an Alzheimer’s Cure

BioWorld’s top 10 stories for 2012 included the puzzling outcome of some massive Alzheimer’s trials. Find out how we are more-sure-than-ever of what ought to work, while still unsure of the cure.


Alzheimer’s drug discovery found itself in a puzzling spot in 2012. Late-stage clinical trials in the indication continued to do what they have been doing for years – fail. This year added Eli Lilly and Co.’s candidate solanezumab, and Pfizer Inc. and Johnson & Johnson’s bapineuzumab, which originated with Elan Corp. plc, to the rubble heap.

At the same time, several research studies provided the strongest evidence yet that misprocessing of amyloid precursor protein or APP is indeed a cause of Alzheimer’s disease, not just its consequence. In other words, targeting plaques should work – but it doesn’t.

Ideas for how to translate what is understood about the basic science of Alzheimer’s disease into a working drug include starting treatment earlier, and interfering with the very earliest steps of APP processing in order to prevent the formation of oligomer intermediates as well as the plaques that have been the most common target of experimental therapeutics. But in 2012, that translation once again remained elusive.

Two steps forward are discussed in the following posts containing both videos & articles :


SOURCE: BioWorld

Email me when people comment
Notify of
guest

2 Comments
Inline Feedbacks
View all comments
Unknown
Unknown
December 31, 2012 4:32 am

For over a decade the amyloid cascade has been questioned, not because amyloid is unimportant but rather the opposite because it plays a biological role. Amyloid production in all its forms, is a response to brain injury, and required as much as inflammatory mechanisms. While efforts to modulate amyloid may have therapeutic potential, the current focus of amyloid removal has been proven ineffective. Treating to remove amyloid earlier in disease progression or attacking amyloid oligomers is likely to suffer a similar fate. Understanding how the brain maintains normal function as we age will be essential to effective therapeutics that work with rather than against our biology.

wwl4bbc
wwl4bbc
December 30, 2012 2:11 pm

We`ve got to KEEP trying!

Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

2
0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter
Free

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Care & Treatment. Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter